Abstract:
Schistosomiasis, also called bilharziasis, is a neglected tropical disease induced by schistosomes that infects hundreds of millions of people worldwide. In the life cycle of schistosomiasis, eggs are regarded as the main pathogenic factor, causing granuloma formation in the tissues and organs of hosts, which can cause severe gastrointestinal and liver granulomatous immune responses and irreversible fibrosis. Increasing evidence suggests that the gut microbiome influences the progression of schistosomiasis and plays a central role in liver disease via the gut-liver axis. When used as pharmaceutical supplements or adjunctive therapy, probiotics have shown promising results in preventing, mitigating, and even treating schistosomiasis. This review elucidates the potential mechanisms of this three-way parasite-host-microbiome interaction by summarizing schistosome-mediated intestinal flora disorders, local immune changes, and host metabolic changes, and elaborates the important role of the gut microbiome in liver disease after schistosome infection through the gut-liver axis. Understanding the mechanisms behind this interaction may aid in the discovery of probiotics as novel therapeutic targets and sustainable control strategies for schistosomiasis.
摘要:
血吸虫病,也称为Bilharziasis,是由血吸虫引起的一种被忽视的热带病,感染了全球数亿人。在血吸虫病的生命周期中,鸡蛋被认为是主要的致病因素,在宿主的组织和器官中引起肉芽肿的形成,可引起严重的胃肠道和肝脏肉芽肿免疫反应和不可逆的纤维化。越来越多的证据表明,肠道微生物组会影响血吸虫病的进展,并通过肠-肝轴在肝病中发挥重要作用。当用作药物补充剂或辅助治疗时,益生菌在预防,缓解,甚至治疗血吸虫病。这篇综述通过总结血吸虫介导的肠道菌群紊乱,阐明了这种三向寄生虫-宿主-微生物组相互作用的潜在机制。局部免疫变化,和宿主的代谢变化,并通过肠-肝轴阐述了肠道菌群在血吸虫感染后肝病中的重要作用。了解这种相互作用背后的机制可能有助于发现益生菌作为血吸虫病的新治疗靶标和可持续控制策略。